financetom
Business
financetom
/
Business
/
AIM ImmunoTech Doses First Subject in Phase 2 of Late-Stage Pancreatic Cancer Study
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
AIM ImmunoTech Doses First Subject in Phase 2 of Late-Stage Pancreatic Cancer Study
Feb 25, 2025 8:25 AM

11:14 AM EST, 02/25/2025 (MT Newswires) -- AIM ImmunoTech ( AIM ) said Tuesday it has dosed the first new subject in phase 2 of a phase 1b/2 clinical trial evaluating the company's Ampligen and AstraZeneca's ( AZN ) Imfinzi as a potential combination to treat late-stage pancreatic cancer.

Phase 2 will also include various subjects who received the highest dose, AIM said.

The company said that up to 25 patients are expected to be enrolled in the study's phase 2.

AIM shares were down over 8% in recent trading.

Price: 0.12, Change: -0.01, Percent Change: -8.44

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved